Helix BioPharma Corp. To Present At Up and Coming Bio Investor Forum in San Francisco

(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company’s Chief Executive Officer, Dr. Sven Rohmann, will present a corporate overview at the Bio Investor Forum on Wednesday October 19th, at 10:00 AM (Pacific) in conference …

Helix BioPharma Corp. To Present At Precision Lung Cancer World R&D Summit

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. Heman Chao, Helix’s CSO, will be presenting: Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer at the Precision Lung …

Helix BioPharma Corp Announces New Director Appointment

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announces the appointment of Dr. Theordore J. Witek, Jr. to the board of directors of Helix.

Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company’s poster entitled: CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer has been accepted for presentation at …